BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+27.77%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.73B
AUM Growth
+$8.73B
(+21%)
Cap. Flow
+$239M
Cap. Flow
% of AUM
2.73%
Top 10 Holdings %
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
81
Reduced
66
Closed
12
Top Buys
| 1 |
Biogen
BIIB
|
$136M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$65.8M |
| 3 |
Mersana Therapeutics
MRSN
|
$51.3M |
| 4 |
Arvinas
ARVN
|
$46.7M |
| 5 |
AbbVie
ABBV
|
$36.3M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$154M |
| 2 |
Halozyme
HALO
|
$60.8M |
| 3 |
Pacific Biosciences
PACB
|
$57.2M |
| 4 |
CareDx
CDNA
|
$55.9M |
| 5 |
Charles River Laboratories
CRL
|
$52M |
Sector Composition
| 1 | Healthcare | 95.9% |
| 2 | Technology | 0.6% |
| 3 | Industrials | 0.33% |
| 4 | Financials | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.79B
| $512M | 5.86% | 9,050,092 +333,822 | +4% | +$18.9M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $326M | 3.73% | 3,396,651 +99,200 | +3% | +$9.51M |
|
3
Moderna
MRNA
$9.37B
| $308M | 3.53% | 2,946,913 -395,037 | -12% | -$41.3M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $293M | 3.35% | 1,238,985 +278,385 | +29% | +$65.8M |
|
5
argenx
ARGX
$43.6B
| $278M | 3.18% | 945,348 -13,668 | -1% | -$4.02M |
|
6
Incyte
INCY
$16.5B
| $262M | 3% | 3,008,700 -270,750 | -8% | -$23.5M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $218M | 2.49% | 1,393,028 -28,100 | -2% | -$4.39M |
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $208M | 2.39% | 1,603,500 +43,695 | +3% | +$5.68M |
|
9
Fate Therapeutics
FATE
$120M
| $192M | 2.19% | 2,107,500 -110,000 | -5% | -$10M |
|
|
10
Arvinas
ARVN
$568M
| $186M | 2.13% | 2,191,503 +550,000 | +34% | +$46.7M |
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $182M | 2.08% | 4,201,002 +50,000 | +1% | +$2.17M |
|
|
12
Halozyme
HALO
$8.56B
| $173M | 1.98% | 4,045,000 -1,424,131 | -26% | -$60.8M |
|
13
Intuitive Surgical
ISRG
$170B
| $160M | 1.84% | 196,020 +42,836 | +28% | +$35M |
|
14
Abbott
ABT
$231B
| $153M | 1.75% | 1,396,873 +108,588 | +8% | +$11.9M |
|
15
CRISPR Therapeutics
CRSP
$4.71B
| $139M | 1.6% | 909,684 -39,578 | -4% | -$6.06M |
|
|
16
Biogen
BIIB
$19.4B
| $138M | 1.58% | 564,000 +555,400 | +6,458% | +$136M |
|
|
SAGE
17
DELISTED
Sage Therapeutics
SAGE
| $136M | 1.55% | 1,567,504 -12,000 | -0.8% | -$1.04M |
|
18
MacroGenics
MGNX
$112M
| $135M | 1.55% | 5,904,517 +622,329 | +12% | +$14.2M |
|
|
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
| $135M | 1.54% | 7,531,414 +100,000 | +1% | +$1.79M |
|
20
Esperion Therapeutics
ESPR
$448M
| $134M | 1.53% | 5,138,451 -327,264 | -6% | -$8.51M |
|
|
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
| $133M | 1.52% | 4,804,039 -287,961 | -6% | -$7.95M |
|
22
Danaher
DHR
$147B
| $119M | 1.36% | 533,794 +80,410 | +18% | +$17.9M |
|
|
ITCI
23
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $116M | 1.33% | 3,659,919 +80,000 | +2% | +$2.54M |
|
24
Bristol-Myers Squibb
BMY
$96B
| $112M | 1.28% | 1,804,472 +158,560 | +10% | +$9.84M |
|
25
Scholar Rock
SRRK
$3.14B
| $111M | 1.27% | 2,286,651 -555,864 | -20% | -$27M |
|